Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

By Mitchell Dowsett, I. Smith, S. Ebbs, J. Dixon, A. Skene, R. A’Hern, J. Salter, S. Detre, M. Hills, G. Walsh. Journal of the National Cancer Institute, 2007

622 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/d4956e55c41fdac4bde78f658dbb47880e2e3200

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Mitchell Dowsett
2. Charles M. Perou
3. S. Leung
4. Torsten O. Nielsen
5. C. Sawyers
6. Balázs Győrffy

In Oncology

1. Charles M. Perou
2. R. Sutherland
3. Masakazu Toi
4. David L. Rimm
5. C. Sawyers
6. E. Musgrove
7. C. Hudis
8. E. Scholar

Citations in the corpus

• The cancer biomarker problem (2008, background): “In most patients, the proportion of tumour cells that were Ki-67 p was smaller than in the pretreatment biopsy sample, and the magnitude of this reduction correlated with progression-free survival (that is, the length of time in which the individual's disease did not worsen”
• Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011, methodology): “For example, in the IMPACT trial (16), the value of Ki67 after 2 weeks of endocrine therapy had a stronger association with time to recurrence compared with pretreatment Ki67 level; moreover, association between pretreatment Ki67 level and time to recurrence was not statistically significant in a mu”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “However, failure to lower Ki-67 offers early identification of a group of patients who should be considered for switch to alternative therapies [82, 83].”
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013, methodology): “Ki-67 has been used for more than two decades as a prognostic marker in early breast cancer [110–118].”
• Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma (2008, background): “Such neoadjuvant studies have been successfully implemented with hormonal agents alone or in combination with kinase inhibitors in breast cancer [4,5].”
• Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020, background): “because it is a derivative of both the prognostic value of baseline Ki67 and the suppressive effect that ET has on Ki67 in responsive patients (81).”
• Biological determinants of endocrine resistance in breast cancer (2009, background): “Although proliferation is reduced in almost all ER-positive breast cancers following neoadjuvant endocrine therapy, the level of proliferation following short-term therapy is a better predictor of outcome than its pretreatment level or the magnitude of the decrease in proliferation following treatme”